Old Web
English
Sign In
Acemap
>
Paper
>
Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naïve CLL: A Phase II Study
Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naïve CLL: A Phase II Study
2019
Sanjal Desai
Dennis C. Drinkwater
Clifton Craig Mo
Mohammed Farooqui
Susan Soto
Janet Valdez
Erika M Gaglione
Xin Tian
Pia Nierman
Jennifer Lotter
Gerald E. Marti
Cydney M. Nichols
Alankrita Taneja
Sarah E. M. Herman
Irina Maric
Laura M Wake
Maryalice Stetler-Stevenson
Constance M. Yuan
Thomas E. Hughes
Margaret A. Lindorfer
Ronald P. Taylor
Adrian Wiestner
Inhye E. Ahn
Keywords:
Chemoimmunotherapy
Ofatumumab
Phases of clinical research
Oncology
Medicine
Immunology
Internal medicine
Disease remission
therapy naive
tumor cells
Fludarabine
genetic risk
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]